Drugs / HS-20108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06936735 | May 2025 → Aug 2028 expected | neoplasm | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06936735 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT06936735 ↗ |